All Stories

  1. Combined Tribenoside/Lidocaine Rectal Cream (Procto-Glyvenol®) Promotes Tissue Repair in a Preclinical Model of Acute Complicated Anal Fissure
  2. The Mediterranean diet: historical benefits and contemporary challenges in Southern Italy
  3. ATTENUATION COEFFICIENT MEASUREMENT IN SCREENING FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: BETWEEN DIAGNOSTIC ACCURACY AND ECONOMIC REALITY
  4. Different association of gBRCA1 and gBRCA2 variants with HER2-low status in invasive breast cancer: findings from a Ukrainian study
  5. Accuracy of attenuation coefficient measurement (ACM) for hepatic steatosis: comparison with MRI proton density fat fraction (MRI-PDFF) and chemical fat analysis using multimodal liver fat phantoms
  6. Accuracy of the hepatorenal index with additional standardized acoustic depth assessment for steatotic liver disease diagnosis
  7. Biological and Therapeutic Potentials of MXenes in Tumor Microenvironment-Driven Oncology
  8. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  9. Dapagliflozin in the Strategy of Secondary Prevention of Ischaemic Heart Disease: Clinical Results in Patients with Post-Myocardial Infarction Cardiosclerosis
  10. Systemic Modulation of Inflammation and Vascular Remodelling in a Stable Post-Infarction Cohort under the Influence of Losartan
  11. Editorial: Fecal Microbiota Transplants: challenges in translating microbiome research to clinical applications
  12. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  13. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  14. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
  15. Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes
  16. Efficacy of Losartan within a Multicomponent Secondary Prevention Strategy for Cardiovascular Events in Post-Ischemic Stroke Patients
  17. Integration of dapagliflozin into a multicomponent therapeutic strategy of secondary prevention in patients with type 2 diabetes mellitus after myocardial infarction
  18. GBD 2023 Cardiovascular Disease Collaborators
  19. Relationship between leukocyte telomere length and early markers of kidney damage in people with type 2 diabetes
  20. Association of leukocyte telomere length and HbA1c with post-COVID-19 syndrome in type 2 diabetes: a cross-sectional pilot study
  21. Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study
  22. Genomics of Type 1 Diabetes in Ukraine Initiative
  23. Features of correction of vitamin D deficiency in patients with diabetic kidney disease: the role of vitamin D-binding protein
  24. Early markers of renal damage in type 2 diabetes: role of vitamin D-binding protein
  25. Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
  26. Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling
  27. Immune cells in thyroid adenoma and carcinoma: uncovering a hidden value of assessing tumor-host interplay and its potential application in thyroid cytopathology
  28. The impact of war on people with type 2 diabetes in Ukraine: a survey study
  29. Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes
  30. HbA1c and leukocyte mtDNA levels as major factors associated with post-COVID-19 syndrome in type 2 diabetes patients
  31. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
  32. Early diagnosis of mineral and bone disorders in patients with diabetic kidney disease on the background of type 2 diabetes
  33. Corrigendum to: ’Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3’ [Biomed. Pharmacother. (2023) 115176/165]
  34. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
  35. Association between intestinal microflora and obesity
  36. Digital pathology implementation in cancer diagnostics: towards informed decision-making
  37. Microbiota substances modulate dendritic cells activity: A critical view
  38. Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials
  39. Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas
  40. Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
  41. Accuracy Assessment of Attenuation Coefficient Measurement For Ultrasound Hepatic Steatometry by Comparing Multimodal Performance Findings with Mri-Pdff And Chemical Analysis of Fat Content
  42. Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
  43. Ethical navigation of biobanking establishment in Ukraine: learning from the experience of developing countries
  44. Accuracy of attenuation coefficient measurement (ACM) for real-time ultrasound hepatic steatometry: Comparison of simulator/phantom data with magnetic resonance imaging proton density fat fraction (MRI-PDFF)
  45. Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
  46. Probiotics for pancreatic β-cell function: from possible mechanism of action to assessment of effectiveness
  47. Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3
  48. Antimicrobial activity of dietary supplements based on bacterial lysate of Lactobacillus rhamnosus DV
  49. The detrimental consequences of two consecutive disasters impacting cytopathology in Ukraine: COVID followed by the war
  50. Incidence of BRAF Mutations in Cutaneous Melanoma: Histopathological and Molecular Analysis of a Ukrainian Population
  51. Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method
  52. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
  53. Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial
  54. Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option
  55. Microbiome and Obesity
  56. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
  57. Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3
  58. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial
  59. Resveratrol Effects on the Reproductive System in Ovariectomized Rats: Deciphering Possible Mechanisms
  60. Nutrition program, physical activity and gut microbiota modulation: a randomized controlled trial to promote a healthy lifestyle in students with vitamin D3 deficiency
  61. Precision oncology: ethical challenges and justification
  62. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders
  63. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
  64. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
  65. Global multi-stakeholder endorsement of the MAFLD definition
  66. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment
  67. Correction of Androgen Deficiency in Men with Type 2 Diabetes
  68. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
  69. Gut Microbiota Interactions With Obesity
  70. SEMI-QUANTITATIVE EVALUATION OF THE HEPATIC AND PANCREATIC STEATOSIS BY GRAY SCALE ECHOGENICITY
  71. STRATIFICATION OF LIVER STEATOSIS BY THE ATTENUATION COEFFICIENT MEASUREMENT (ACM) OF THE HAND-HELD ULTRASOUND DEVICE
  72. Probiotics and obesity associated disease: an extended view beyond traditional strains
  73. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
  74. Изменения состава микробиоты кишечника, связанные с ожирением: новые результаты метагеномного анализа
  75. Оценка клинической эффективности заместительной терапии препаратом Декап у пациентов с сахарным диабетом типа 2 и сопутствующей неалкогольной жировой болезнью печени при дефиците витамина D
  76. Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle
  77. Alleviation of halitosis by use of probiotics and their protective mechanisms in the oral cavity
  78. Immunomodulatory role of Faecalibacterium prausnitzii in obesity and metabolic disorders
  79. Microbial and immune markers of patients with metabolic syndrome and cardiovascular diseases: perspectives for early diagnostics
  80. Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: a critical view during COVID-19 time
  81. Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial
  82. Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis
  83. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
  84. Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri
  85. Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes
  86. Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders
  87. Probiotic and omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance, improves glycemia and obesity parameters in individuals with type 2 diabetes: A randomised controlled trial
  88. Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes
  89. Probiotics function and modulation of the immune system in allergic diseases
  90. Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment
  91. Combined effects of probiotic and chondroprotector during osteoarthritis in rats
  92. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
  93. Crosstalk between gut microbiota and osteoarthritis: A critical view
  94. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
  95. New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study
  96. Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells
  97. Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study
  98. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
  99. Effect of probiotic on serum cytokines and matrix metalloproteinases profiles during monoiodoacetate-induced osteoarthritis in rats
  100. Crosstalk between gut microbiota and antidiabetic drug action
  101. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
  102. Neuropathic diabetic foot ulcers treated with cerium dioxide nanoparticles: A case report
  103. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
  104. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
  105. Polyphenol Compounds Melanin Prevented Hepatic Inflammation in Rats with Experimental Obesity
  106. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
  107. Wpływ Z56822977 na biosyntezę serotoniny w mózgu szczurów z otyłością wywołaną przez podawanie glutaminianu sodu
  108. The correction of the metabolic parameters of msg-induced obesity in rats by 2-[4-(benzyloxy) phenoxy] acetic acid
  109. Probiotics and nutraceuticals as a new frontier in obesity prevention and management
  110. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial
  111. The role of nanotechnology in food safety
  112. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ca...
  113. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial
  114. Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease
  115. Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders
  116. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats
  117. H 2 S causes contraction and relaxation of major arteries of the rabbit
  118. Effects of polyphenol compounds melanin on NAFLD/NASH prevention
  119. The Impact of Hyperglycemia on VEGF Secretion in Retinal Endothelial Cells
  120. Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan)
  121. Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial
  122. Nanocrystalline cerium dioxide efficacy for prophylaxis of erosive and ulcerative lesions in the gastric mucosa of rats induced by stress
  123. Perspectives and challenges of antioxidant therapy for atrial fibrillation
  124. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
  125. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity
  126. The Role of Liver Biopsy to Assess Alcoholic Liver Disease
  127. Prevention of NAFLD development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles
  128. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention
  129. Caffeine and cardiovascular diseases: critical review of current research
  130. Probiotics in prevention and treatment of obesity: a critical view
  131. Pathophysiological role of host microbiota in the development of obesity
  132. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition
  133. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility
  134. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients
  135. P0968 : Are the type of probiotic strains and their amount equally effective for NAFLD prevention? Experimental comparative study
  136. Diagnosis of experimental stetohepatosis using ultrasound shear wave elastography
  137. The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease
  138. Multiprobiotic therapy from childhood prevents the development of nonalcoholic fatty liver disease in adult monosodium glutamate-induced obese rats
  139. P269 SHORT-TERM PERIODIC ADMINISTRATION OF MULTIPROBIOTIC FROM CHILDHOOD PREVENTS DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN ADULT MONOSODIUM GLUTAMATE-INDUCED OBESE RATS
  140. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
  141. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity
  142. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity
  143. 1329 DIAGNOSTIC ACCURACY OF A NEW ELASTOGRAPHIC METHOD (SHEAR WAVE™ ELASTOGRAPHY IMAGING) IN THE NONINVASIVE ASSESSMENT OF NON-ALCOHOLIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES
  144. 1267 PERFORMANCE OF NEW ULTRASOUND METHOD FOR ASSESSING LIVER STIFFNESS – SHEAR WAVE™ ELASTOGRAPHY IMAGING IN RATS WITH EXPERIMENTAL OBESITY